Mission Bio secures equity financing led by Ally Bridge Group to enhance its single-cell tri-omics platform and drive commercial growth.

Aug 05, 2025•5 months ago

San FranciscoresearchBiotechnology

Investors

Ally Bridge Group

Description

Mission Bio completed an equity financing to support innovations and clinical adoption of its Tapestri® Platform across cancer segments. This funding aims to advance single-cell tri-omics capabilities. The financing follows strong traction with biopharma customers and platform innovation. Mission Bio will expand its offerings for characterizing tri-omics at high resolution.

Company Information

Company

Mission Bio

Location

400 E Jamie Ct, Suite 100

San Francisco, California, United States

About

Mission Bio is the single-cell tri-omics leader. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods, such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns